Cargando…

Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin

BACKGROUND: SGLT2 (sodium/glucose cotransporter 2) inhibitors exert robust cardioprotective effects against heart failure in patients with diabetes, and there is intense interest to identify the underlying molecular mechanisms that afford this protection. Because the induction of the late component...

Descripción completa

Detalles Bibliográficos
Autores principales:	Philippaert, Koenraad, Kalyaanamoorthy, Subha, Fatehi, Mohammad, Long, Wentong, Soni, Shubham, Byrne, Nikole J., Barr, Amy, Singh, Jyoti, Wong, Jordan, Palechuk, Taylor, Schneider, Chloe, Darwesh, Ahmed M., Maayah, Zaid H., Seubert, John M., Barakat, Khaled, Dyck, Jason R.B., Light, Peter E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154177/ https://www.ncbi.nlm.nih.gov/pubmed/33832341 http://dx.doi.org/10.1161/CIRCULATIONAHA.121.053350

Ejemplares similares

TRPV1 channels as a newly identified target for vitamin D
por: Long, Wentong, et al.
Publicado: (2021)

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
por: Sanon, Vani P, et al.
Publicado: (2017)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
por: Kolwelter, Julie, et al.
Publicado: (2021)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats
por: Yaribeygi, Habib, et al.
Publicado: (2023)

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
por: Ring, Arne, et al.
Publicado: (2013)

Multiple Evanescent White Dot Syndrome Presenting After Initiation of Empagliflozin, a Sodium-Glucose Cotransporter-2 Inhibitor
por: Boutros, Heidi, et al.
Publicado: (2021)

Vitamin D is an endogenous partial agonist of the transient receptor potential vanilloid 1 channel
por: Long, Wentong, et al.
Publicado: (2020)

Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats
por: Lee, Kyung Ae, et al.
Publicado: (2018)

Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events
por: Xie, Yan, et al.
Publicado: (2020)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin
por: Jahir, Tahmina, et al.
Publicado: (2022)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023)

Increased Hematocrit During Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Heyman, Samuel N., et al.
Publicado: (2017)

Iodide Binding in Sodium-Coupled Cotransporters
por: Vergara-Jaque, Ariela, et al.
Publicado: (2017)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice
por: Xue, Genlong, et al.
Publicado: (2022)

Expression of the sodium potassium chloride cotransporter (NKCC1) and sodium chloride cotransporter (NCC) and their effects on rat lens transparency
por: Chee, K.N., et al.
Publicado: (2010)

Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects
por: Biancalana, Edoardo, et al.
Publicado: (2023)

Structure-function relationships in the sodium chloride cotransporter
por: Moreno, Erika, et al.
Publicado: (2023)

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
por: Byrne, Nikole J., et al.
Publicado: (2017)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
por: Sano, Ryuhei, et al.
Publicado: (2020)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Mechanism of Dyslipidemia in Obesity—Unique Regulation of Ileal Villus Cell Brush Border Membrane Sodium–Bile Acid Cotransport
por: Sundaram, Shanmuga, et al.
Publicado: (2019)

Chronic exogenous ketone supplementation blunts the decline of cardiac function in the failing heart
por: Takahara, Shingo, et al.
Publicado: (2021)

Subcutaneous white adipocytes express a light sensitive signaling pathway mediated via a melanopsin/TRPC channel axis
por: Ondrusova, Katarina, et al.
Publicado: (2017)

Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
por: Al-Shamasi, Al-Anood, et al.
Publicado: (2021)

Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy
por: Ren, Changzhen, et al.
Publicado: (2021)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

Structural models of the NaPi-II sodium-phosphate cotransporters
por: Fenollar-Ferrer, Cristina, et al.
Publicado: (2018)

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1
por: Park, Jiyoung, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vesab2ktduteieqtnprb4cc6qp